Medicus Pharma initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $14 price target Medicus is a development-stage biotechnology company focused on commercializing a novel, non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle array that delivers doxorubicin directly to tumor cells, the analyst tells investors in a research note. The firm says that for a strategic buyer, Medicus offers a “de-risked entry into niche indications, optionality on platform expansion, and the opportunity to leverage internal regulatory and commercialization infrastructure to accelerate value realization.”